Biotron Limited (BITRF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -386.06 Thousand AUD | 90.2% |
| 2023 | -3.93 Million AUD | -136.7% |
| 2022 | -1.66 Million AUD | 60.42% |
| 2021 | -4.2 Million AUD | 44.8% |
| 2020 | -7.61 Million AUD | -32.7% |
| 2019 | -5.73 Million AUD | -271.99% |
| 2018 | -1.54 Million AUD | 22.36% |
| 2017 | -1.98 Million AUD | 41.86% |
| 2016 | -3.41 Million AUD | 24.42% |
| 2015 | -4.52 Million AUD | -156.39% |
| 2014 | -1.76 Million AUD | 63.19% |
| 2013 | -4.79 Million AUD | 39.27% |
| 2012 | -7.89 Million AUD | -267.94% |
| 2011 | -2.14 Million AUD | -20.46% |
| 2010 | -1.78 Million AUD | -87.31% |
| 2009 | -950.58 Thousand AUD | 53.94% |
| 2008 | -2.06 Million AUD | -49.67% |
| 2007 | -1.37 Million AUD | 70.18% |
| 2006 | -4.62 Million AUD | -118.84% |
| 2005 | -2.11 Million AUD | 19.29% |
| 2004 | -2.61 Million AUD | 51.3% |
| 2003 | -5.37 Million AUD | 29.07% |
| 2002 | -7.57 Million AUD | 21.98% |
| 2001 | -9.71 Million AUD | 11.87% |
| 2000 | -11.02 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -721.68 Thousand AUD | 56.63% |
| 2024 FY | -386.06 Thousand AUD | 90.2% |
| 2024 Q4 | -386.06 Thousand AUD | 1.81% |
| 2024 Q2 | -693.63 Thousand AUD | 3.89% |
| 2024 Q3 | -393.19 Thousand AUD | 43.31% |
| 2023 Q2 | -6.4 Million AUD | 0.41% |
| 2023 FY | -3.93 Million AUD | -136.7% |
| 2023 Q1 | -6.43 Million AUD | -286.65% |
| 2023 Q4 | -1.66 Million AUD | 58.16% |
| 2023 Q3 | -3.97 Million AUD | 37.93% |
| 2022 FY | -1.66 Million AUD | 60.42% |
| 2022 Q2 | -2.25 Million AUD | 1.44% |
| 2022 Q3 | -1.69 Million AUD | 24.83% |
| 2022 Q1 | -2.29 Million AUD | 45.47% |
| 2022 Q4 | -1.66 Million AUD | 2.02% |
| 2021 Q3 | -4.21 Million AUD | 17.83% |
| 2021 Q4 | -4.2 Million AUD | 0.15% |
| 2021 Q1 | -5.15 Million AUD | 32.38% |
| 2021 FY | -4.2 Million AUD | 44.8% |
| 2021 Q2 | -5.12 Million AUD | 0.5% |
| 2020 Q2 | -8.61 Million AUD | 0.41% |
| 2020 FY | -7.61 Million AUD | -32.7% |
| 2020 Q4 | -7.61 Million AUD | 0.53% |
| 2020 Q1 | -8.64 Million AUD | -50.66% |
| 2020 Q3 | -7.65 Million AUD | 11.08% |
| 2019 FY | -5.73 Million AUD | -271.99% |
| 2019 Q1 | -6.99 Million AUD | -353.38% |
| 2019 Q2 | -6.99 Million AUD | 0.0% |
| 2019 Q4 | -5.73 Million AUD | 0.0% |
| 2019 Q3 | -5.73 Million AUD | 17.95% |
| 2018 Q3 | -1.54 Million AUD | 0.98% |
| 2018 Q4 | -1.54 Million AUD | 0.0% |
| 2018 Q2 | -1.55 Million AUD | 0.0% |
| 2018 Q1 | -1.55 Million AUD | 21.59% |
| 2018 FY | -1.54 Million AUD | 22.36% |
| 2017 Q4 | -1.98 Million AUD | 0.0% |
| 2017 Q3 | -1.98 Million AUD | -39.35% |
| 2017 Q2 | -1.42 Million AUD | 0.0% |
| 2017 Q1 | -1.42 Million AUD | 58.28% |
| 2017 FY | -1.98 Million AUD | 41.86% |
| 2016 Q3 | -3.41 Million AUD | 4.29% |
| 2016 FY | -3.41 Million AUD | 24.42% |
| 2016 Q2 | -3.57 Million AUD | 0.0% |
| 2016 Q1 | -3.57 Million AUD | 21.03% |
| 2016 Q4 | -3.41 Million AUD | 0.0% |
| 2015 Q2 | -3.06 Million AUD | 0.0% |
| 2015 FY | -4.52 Million AUD | -156.39% |
| 2015 Q4 | -4.52 Million AUD | 0.0% |
| 2015 Q3 | -4.52 Million AUD | -47.81% |
| 2015 Q1 | -3.06 Million AUD | -73.46% |
| 2014 FY | -1.76 Million AUD | 63.19% |
| 2014 Q4 | -1.76 Million AUD | 0.0% |
| 2014 Q3 | -1.76 Million AUD | 17.9% |
| 2014 Q1 | -2.14 Million AUD | 55.16% |
| 2014 Q2 | -2.14 Million AUD | 0.0% |
| 2013 Q3 | -4.79 Million AUD | 0.0% |
| 2013 Q4 | -4.79 Million AUD | 0.0% |
| 2013 FY | -4.79 Million AUD | 39.27% |
| 2012 FY | -7.89 Million AUD | -267.94% |
| 2012 Q4 | -7.89 Million AUD | 0.0% |
| 2011 Q4 | -2.14 Million AUD | 0.0% |
| 2011 FY | -2.14 Million AUD | -20.46% |
| 2010 FY | -1.78 Million AUD | -87.31% |
| 2010 Q4 | -1.78 Million AUD | 0.0% |
| 2009 Q4 | -950.58 Thousand AUD | 0.0% |
| 2009 FY | -950.58 Thousand AUD | 53.94% |
| 2008 Q4 | -2.06 Million AUD | 0.0% |
| 2008 FY | -2.06 Million AUD | -49.67% |
| 2007 Q4 | -1.37 Million AUD | 0.0% |
| 2007 FY | -1.37 Million AUD | 70.18% |
| 2006 FY | -4.62 Million AUD | -118.84% |
| 2006 Q4 | -4.62 Million AUD | 0.0% |
| 2005 FY | -2.11 Million AUD | 19.29% |
| 2005 Q4 | -2.11 Million AUD | 0.0% |
| 2004 FY | -2.61 Million AUD | 51.3% |
| 2004 Q4 | -2.61 Million AUD | 0.0% |
| 2003 Q4 | -5.37 Million AUD | 0.0% |
| 2003 FY | -5.37 Million AUD | 29.07% |
| 2002 Q4 | -7.57 Million AUD | 0.0% |
| 2002 FY | -7.57 Million AUD | 21.98% |
| 2001 FY | -9.71 Million AUD | 11.87% |
| 2001 Q4 | -9.71 Million AUD | 0.0% |
| 2000 FY | -11.02 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 102.449% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 109.375% |
| SQZ Biotechnologies Company | -36.23 Million USD | 98.935% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.902% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 93.876% |
| Mesoblast Limited | 55.85 Million USD | 100.691% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 141.639% |
| Genus plc | 190.6 Million USD | 100.203% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 117.267% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 131.804% |
| Marizyme, Inc. | 18.56 Million USD | 102.079% |
| ContraFect Corporation | -6.02 Million USD | 93.593% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 156.775% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 386.743% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 133.413% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 117.218% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 107.017% |
| MultiCell Technologies, Inc. | 90.04 USD | 428873.878% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 47.401% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 102.982% |
| EV Biologics, Inc. | 1.36 Million USD | 128.222% |
| Q BioMed Inc. | 4.06 Million USD | 109.509% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 101.264% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 162.033% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 138.311% |
| Biomind Labs Inc. | 711.4 Thousand USD | 154.269% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 100.352% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 103.015% |
| Skye Bioscience, Inc. | -5.72 Million USD | 93.252% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 144.879% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 376.149% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 106.835% |
| IMV Inc. | 7.67 Million USD | 105.033% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 2043.263% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 117.533% |
| GB Sciences, Inc. | 1.74 Million USD | 122.095% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -110.062% |
| HST Global, Inc. | 96.79 Thousand USD | 498.859% |
| CSL Limited | 10.52 Billion USD | 100.004% |
| Halberd Corporation | 144.72 Thousand USD | 366.767% |
| Enzolytics Inc. | 981.65 Thousand USD | 139.328% |
| Resverlogix Corp. | 6.45 Million USD | 105.985% |
| Affymax, Inc. | -5.59 Million USD | 93.102% |
| SYBLEU INC | 473.71 Thousand USD | 181.498% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 42.642% |
| argenx SE | -2.02 Billion USD | 99.981% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.889% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.179% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 114.253% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 95.633% |
| AVAX Technologies, Inc. | -5.9 Million USD | 93.46% |
| Zenith Capital Corp. | 10.06 Thousand USD | 3936.129% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.964% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 292.618% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 116.18% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 334.679% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.638% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 119.309% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 84.978% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 207.328% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 101.904% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -2007.588% |
| BioStem Technologies, Inc. | 4.47 Million USD | 108.633% |
| ONE Bio Corp. | 9.04 Million USD | 104.271% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 291.831% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -29370.84% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 287.214% |
| Agentix Corp. | 37.63 Thousand USD | 1125.931% |
| LadRx Corporation | -2.03 Million USD | 81.042% |
| Cell Source, Inc. | 9.23 Million USD | 104.182% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1791.748% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 160.782% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 160.782% |
| NovAccess Global Inc. | 2.17 Million USD | 117.722% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 105.46% |
| Itoco Inc. | 228.3 Thousand USD | 269.102% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 383.896% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 107.788% |
| Kadimastem Ltd | -253.1 Thousand USD | -52.535% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 196.073% |
| CytoDyn Inc. | 20.26 Million USD | 101.905% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -59570.479% |
| Mobile Lads Corp. | 484.23 Thousand USD | 179.728% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -4065.449% |
| Qrons Inc. | 351.42 Thousand USD | 209.857% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 105.01% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -54.662% |
| Rebus Holdings, Inc. | 305 Thousand USD | 226.58% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 108.662% |
| International Stem Cell Corporation | 2.59 Million USD | 114.906% |
| Bioxytran, Inc. | 1.89 Million USD | 120.331% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 718.57% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 117.702% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 111.243% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 104.514% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 149.97% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 69.115% |
| Neutra Corp. | 52.18 Thousand USD | 839.778% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 84.489% |
| PureTech Health plc | -167.19 Million USD | 99.769% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -57.638% |
| IXICO plc | -4.44 Million USD | 91.314% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 102.921% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.704% |
| CSL Limited | 10.52 Billion USD | 100.004% |
| Cellectis S.A. | -43.81 Million USD | 99.119% |